[1] FDA. ISTODAX(romidepsin) Label[EB/OL]. FDA News， November 5， 2009.http：//www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf. [2] PANICKER J， LI Z， MCMAHON C， et al. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells[J]. Cell Cycle， 2010， 9(9)：1830-1838. [3] WOO S， GARDNER E R， CHEN X， et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma[J]. Clin Cancer Res， 2009， 15(4)：1496-1503. [4] BATES S E， ZHAN Z， STEADMAN K， et al. Laboratory correlates for a phase Ⅱ trial of romidepsin in cutaneous and peripheral T-cell lymphoma[J]. Br J Haematol， 2010， 148(2)：256-267. [5] PIEKARZ R L， FRYE R， TURNER M， et al. Phase Ⅱ multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma[J]. J Clin Oncol， 2009， 27(32)：5410-5417.
PDF(349 KB)
